HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SILO
Silo Pharma, Inc.
There isn't enough reported data to score SILO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SILO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SILO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SILO PE Valuation
SILO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SILO Forward outlook
There aren't enough analyst estimates for SILO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
SILO has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus SILO down 177%.
SILO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$13.80 | +$4.07 |
| Q2 2025 | -$15.30 | +$2.42 |
| Q1 2025 | -$17.10 | +$0.77 |
| Q4 2024 | -$17.85 | +$0.17 |
| Q3 2024 | -$17.87 | +$12.45 |
| Q2 2024 | -$17.72 | +$16.80 |
| Q1 2024 | -$17.87 | +$19.35 |
| Q4 2023 | -$18.02 | +$14.85 |
SILO is still losing money, but far less than before: $13.80 per share over the past year, against $52.50 at its worst in mid-2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SILO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SILO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $18K | 0% |
| Q4 2025 | $18K | 0% |
| Q3 2025 | $18K | 0% |
| Q2 2025 | $18K | 0% |
| Q1 2025 | $18K | 0% |
| Q4 2024 | $18K | 0% |
| Q3 2024 | $18K | 0% |
| Q2 2024 | $18K | 0% |
SILO's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -8846% | -2777 points |
| Q4 2025 | -4363% | +5696 points |
| Q3 2025 | -6388% | -785 points |
| Q2 2025 | -6927% | -1364 points |
| Q1 2025 | -6070% | -1191 points |
| Q4 2024 | -10060% | -3604 points |
| Q3 2024 | -5604% | -1313 points |
| Q2 2024 | -5563% | +623 points |
SILO's operating margin was −8846% last quarter, down 2777 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SILO on cash generation, producing positive trailing cash flow while its opponent burns cash.
SILO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$781.9K | +$503.4K |
| Q1 2026 | -$822.6K | +$817.7K |
| Q4 2025 | -$780.3K | +$137.2K |
| Q3 2025 | -$955.5K | +$391K |
| Q2 2025 | -$1.3M | -$553.5K |
| Q1 2025 | -$1.6M | -$802.1K |
| Q4 2024 | -$917.4K | -$7.4K |
| Q3 2024 | -$1.3M | -$274.7K |
SILO has burned cash in almost every quarter: −$3M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SILO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SILO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +185K shares |
| 1 year | +267% | +800K shares |
| 3 years | +422% | +888K shares |
| 5 years | +876% | +986K shares |
| Available history | +3411% | +1.1M shares |
SILO has 1M diluted shares, up 267% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SILO Net Leverage
SILO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SILO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 12.9 | Oversold |
SILO's weekly RSI is 35 (neutral) and its Stochastic is 13 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SILO PE vs Healthcare Sector
| Metric | SILO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SILO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SILO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 33% above |
| 20 week MA | $2.77 | 31% below |
| 50 week MA | $4.58 | 58% below |
| 100 week MA | $8.91 | 79% below |
| 200 week MA | $17.4 | 89% below |
SILO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SILO on returns for 2026, with the stronger performance.
SILO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $262.5 | $101.3 | -61% |
| 2022 | $101.3 | $45.0 | -56% |
| 2023 | $45.0 | $21.6 | -52% |
| 2024 | $21.6 | $14.1 | -35% |
| 2025 | $14.1 | $5.47 | -61% |
| 2026 YTD | $5.47 | $1.91 | -65% |
SILO has finished every year since 2021 lower, and it's down 65% so far in 2026.